Published in final edited form as:

Biochemistry. 2009 April 14; 48(14): 3068–3077. doi:10.1021/bi900167q.

Uridine-based inhibitors as new leads for antibiotics targeting *E. coli* LpxC

Adam W. Barb^{†,†}, Tanya M. Leavy[‡], Lori I. Robins[†], Ziqiang Guan[†], David A. Six[†], Pei Zhou[†], Carolyn R. Bertozzi^{‡,§}, and Christian R.H. Raetz^{†,*}

[†] Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

[‡] Department of Chemistry, Center for New Directions in Organic Synthesis, University of California, Berkeley, Berkeley, California 94720

[§] Howard Hughes Medical Institute and Department of Molecular and Cell Biology

Abstract

The UDP-3-*O*-(*R*-3-hydroxyacyl)-*N*-acetylglucosamine deacetylase LpxC catalyzes the committed reaction of lipid A (endotoxin) biosynthesis in Gram-negative bacteria and is a validated antibiotic target. Although several previously described compounds bind to the unique acyl chain binding passage of LpxC with high affinity, strategies to target the enzyme's UDP-binding site have not been reported. Here the identification of a series of uridine-based LpxC inhibitors is presented. The most potent examined, 1-68A, is a pH-dependent, two-step, covalent inhibitor of *E. coli* LpxC that competes with UDP to bind the enzyme in the first step of inhibition. Compound 1-68A exhibits a K_I of 54 μ M and a maximal rate of inactivation (k_{inact}) of 1.7 min⁻¹ at pH 7.4. Dithiothreitol, glutathione and the C207A mutant of *E. coli* LpxC prevent the formation of a covalent complex by 1-68A, suggesting a role for Cys-207 in inhibition. The inhibitory activity of 1-68A and a panel of synthetic analogs identified moieties necessary for inhibition. 1-68A and a 2-dehydroxy analog, 1-68Aa, inhibit several purified LpxC orthologs. These compounds may provide new scaffolds for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket.

With the emergence of multidrug-resistant bacterial infections, there is a critical need for the identification of antibiotics with novel mechanisms of action (1,2) to complement or supplant existing drugs that inhibit protein, nucleic acid or cell wall biosynthesis (3).

The biosynthesis of lipid A (endotoxin), the membrane anchor of lipopolysaccharide, is a promising target for antibiotic design because lipid A is an essential molecule in most Gram-negative bacteria (4). Lipid A is synthesized in the cytoplasm and on the inner surface of the inner membrane by nine unique enzymes (5). The first step is acylation at the 3-OH group of UDP-*N*-acetylglucosamine (Figure 1), followed by the deacetylation of the product UDP-3-*O*-(*R*-3-hydroxyacyl)-*N*-acetylglucosamine (UDP-3-*O*-acyl-GlcNAc), catalyzed by the zinc-dependent enzyme LpxC (6).

Substrate binding by LpxC has been extensively studied using enzyme kinetics, NMR and X-ray crystallography. These studies suggest that the acyl chain of UDP-3-*O*-acyl-GlcNAc binds to LpxC within an unusual hydrophobic passage (7-10). The passage is open at the protein

*Author to whom correspondence should be addressed: C. R. H. Raetz at (919) 684-5326; Fax (919) 684-8885; E-mail: raetz@biochem.duke.edu.

[†]Current Address: Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602

Supporting Information Available: A supplementary figure showing the amino acid alignment of the LpxC orthologs tested in Table 1 is provided. This material is available free of charge via the internet at: <http://pubs.acs.org>

surface, and therefore can accommodate different acyl chain lengths (11,12). The UDP moiety of UDP-3-*O*-acyl-GlcNAc is also critical to substrate binding (13), and a structure of LpxC with bound UDP has revealed the nucleotide binding site (10). Unlike the hydrophobic passage, the UDP binding site has not been exploited in the development of potent LpxC inhibitors.

Low to sub-nanomolar inhibitors targeting LpxC display antibiotic activity (14-17). CHIR-090, the most potent LpxC inhibitor currently available, inhibits a diverse range of LpxC orthologs, generally by a two-step, slow, tight-binding mechanism (14,16). For *E. coli* LpxC the first step of binding is competitive with respect to substrate and exhibits a K_i of 4.0 nM, followed by isomerization to a complex with a K_i^* of 0.5 nM (14). *Rhizobium leguminosarum* LpxC is orders of magnitude (680-fold) less sensitive to CHIR-090 (14), indicating that CHIR-090 does not inhibit all LpxCs with equal potency and thus could be improved to extend the spectrum of inhibition.

The most potent LpxC inhibitors interact with the hydrophobic passage, including CHIR-090 which coordinates the catalytic zinc ion and occupies the hydrophobic passage of *Aquifex aeolicus* LpxC (18). Similarly, the less potent, narrow-spectrum inhibitor L-161,240 (17) also utilizes the hydrophobic passage of *E. coli* LpxC (18). Recent crystallographic evidence suggests another potent LpxC inhibitor, BB-78485 (15), does not penetrate the hydrophobic passage but rather deforms this passage and the active site to cradle the two naphthalene moieties of this compound (19). Neither CHIR-090, BB-78485 nor L-161,240 interact with the UDP-binding site.

To explore the UDP-binding site as a target of future drug design, a uridine-based library was screened for novel LpxC inhibitors. Despite the low probability that such a compound would be an effective drug, the identification of a uridine-containing compound will provide a basis for the development of analogs with more favorable drug properties and provide a new direction for increasing the avidity of existing inhibitors. From this screen compound 1-68A was identified as a two-step covalent inhibitor of *E. coli* LpxC that competes with UDP when binding. Additionally, the inhibition of many purified LpxC orthologs by this compound and a small group of analogs is reported.

Experimental Procedures

Materials, Strains and Reagents

All chemicals, unless otherwise noted, were obtained from Sigma-Aldrich, St. Louis, MO. [α - 32 P]-UTP was purchased from PerkinElmer Life and Analytical Sciences, Inc., Waltham, MA. Plasmid miniprep kits were purchased from Qiagen, Valencia, CA. Primers were purchased from MWG Biotech, High Point, NC. The LpxC inhibitors CHIR-090, L-161,240 and BB-78485 were prepared according to published procedures (18). The uridine-based inhibitor library, 1-68A and 2-68A were synthesized as previously described (20). In aqueous solution 1-68A decomposes in air over the course of 1-2 days, and was stored at -80°C (alternatively, this compound may be stabilized by the addition of DTT or pyruvate).

Assay of LpxC Activity

E. coli LpxC (14), UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine, and [α - 32 P] UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine were prepared as previously described (21). Assays of LpxC activity were performed at pH 7.4 with 5 μ M substrate, except where noted. In experiments including inhibitors dissolved in DMSO, the final concentration of DMSO was 10% (v/v) in each assay. In all experiments, the concentration of the enzyme was at least 10-fold below the concentration of either the inhibitor or the substrate.

Library Screening Conditions

The 1338-membered uridine-based library was compiled into 112 pools, each containing 500 μ M of 12 compounds in 60% DMSO. Pools were diluted 1:10 into an assay of *E. coli* LpxC containing 25 mM NaPO₄, pH 7.4, 1 mg / mL bovine serum albumin (BSA), and 5 μ M [α -³²P]UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine. Each reaction was initiated with 0.1 nM enzyme with a final volume of 5 μ L and incubated for 30 min at 23 °C. Reactions were quenched with 2 μ L of 1.25 M NaOH and incubated for 15 min at 23 °C to hydrolyze the 3-*O*-linked acyl chain of the substrate and product. Reactions were subsequently neutralized with 2 μ L of 1.25 M acetic acid, and protein was precipitated with 1 μ L of 5% trichloroacetic acid. UDP-*N*-acetylglucosamine was separated from UDP-glucosamine using a PEI cellulose thin-layer chromatography plate (EMD Chemicals, Gibbstown, NJ) developed in 0.2 M guanidine hydrochloride. Dried TLC plates were exposed to a PhosphorImager screen and analyzed using a Storm 840 PhosphorImager (GE Healthcare, Chalfont St. Giles, Buckinghamshire, U.K.).

Inhibitor pools showing 40% or greater inhibition of *E. coli* LpxC activity were rescreened to identify the active compounds. Individual compounds were assayed in concentrations ranging from 1 to 500 μ M using the same assay conditions described above, while maintaining 10% DMSO in the assay. Compounds demonstrating favorable dose-response curves were further analyzed by fitting an IC₅₀ value using Equation 1:

$$v_i / v_o = 1 / (1 + I / IC_{50})^H \quad (\text{Eq. 1})$$

in which v_i is the initial velocity of an inhibited reaction, v_o is the initial velocity of an uninhibited reaction, I is the concentration of inhibitor, IC_{50} is the inhibitor concentration at which 50% inhibition of activity is observed, and H is the Hill slope describing the steepness of the curve.

Rapid Dilution and Dialysis of the *E. coli* LpxC – 1-68A complex

E. coli LpxC (1 μ M) was incubated with 50 μ M 1-68A in a buffer containing 1 mg/mL BSA and 25 mM sodium phosphate, pH 7.4 at 30°C for 30 min, then diluted 1:2500 with 1 mg/ml BSA and 25 mM sodium phosphate, pH 7.4. This solution was further diluted 1:4 at timed intervals into an LpxC reaction mixture as described above, where a linear reaction velocity was measured and compared to a control reaction that was incubated and diluted as described above, except with 0 μ M 1-68A.

After incubating 5 mL of a mixture containing 2.5 nM *E. coli* LpxC, 50 μ M 1-68A, 1 mg/mL BSA and 25 mM sodium phosphate, pH 7.4 at 30°C for 30 min, this mixture was loaded into a Slyde-A-Lyzer® 10K dialysis cassette (Pierce) and dialyzed against 1 L of 25 mM sodium phosphate, pH 7.4 at 4°C. At timed intervals, aliquots were removed, tested for activity and compared to a control reaction as described for the rapid dilution experiment.

Determination of the Mechanism of 1-68A binding to *E. coli* LpxC

Product accumulation data with varying concentrations of 1-68A were fitted with the equation describing irreversible time-dependent inhibition (22):

$$P = (v_i / k_{obs}) [1 - \exp(-k_{obs}t)] + C \quad (\text{Eq. 2})$$

in which P is the concentration of product at time t, v_i is the initial velocity, k_{obs} is the observed first order exponential term for the formation of the E-I complex and C is a constant.

It was observed that a plot of k_{obs} versus 1-68A concentration was hyperbolic and thus indicative of a two-step mechanism (Scheme 1), therefore these data were fitted with the equation:

$$k_{obs} = k_{inact} / (1 + (K_I / I)) \quad (\text{Eq. 3})$$

in which k_{inact} is the maximal rate of inactivation, K_I is a kinetic constant describing the inhibitor concentration at which the formation of the E-I complex occurs at one-half the maximal rate (k_{inact}) (22), and I is the concentration of 1-68A in the assay.

Determining the binding mode of 1-68A

Eq. 2 was fitted to reaction progress curves determined over a range of substrate concentrations ($\sim 0.2 - 5 \times K_M$) and 10 or 25 μM 1-68A to extract a k_{obs} value for each condition. These k_{obs} values were plotted against the substrate concentration (S) and fitted with Equation 4:

$$k_{obs} = k_{inact} / (1 + (K_I / I) (1 + S / K_M)) \quad (\text{Eq. 4})$$

in which K_M is the Michaelis constant for *E. coli* LpxC (14), k_{inact} was determined from Eq. 3, and K_I is defined above.

UDP Competition Studies

E. coli LpxC (250 nM) was incubated with 50 μM 1-68A with or without 100 mM UDP at 30 °C in 200 mM sodium phosphate, pH 7.4, and 1 mg / mL BSA. Portions were removed at various time points and immediately diluted 1:400 into a prewarmed LpxC reaction mixture (as described above). The initial reaction velocity (v_i) at each time point was compared to that of a reaction containing enzyme diluted from a control incubation (v_o) containing *E. coli* LpxC (250 nM) in 200 mM sodium phosphate, pH 7.4, and 1 mg / mL BSA.

Electrospray Ionization Mass Spectrometry (ESI-MS) analysis

Liquid-chromatography (LC)-MS was performed as previously described (16), except LpxC was analyzed using a Vydac C4 reverse-phase column (2.1 $\times$ 50 mm). *N*-acetylcysteine-methylester and 1-68A were analyzed using a Vydac C8 column. *E. coli* LpxC and 1-68A were incubated at 15 μM each in a buffer containing 25 mM sodium phosphate, pH 7.4 and 10% DMSO for 1 h at 23 °C. Control samples were prepared that contained each component alone. *N*-acetylcysteine-methylester (1 mM) and 1-68A (0.6 mM) were incubated in a buffer containing 50 mM TRIS, pH 7.6 for 4 h at 23 °C. Proteolysis utilized Proteomics Grade Trypsin (T6567, Sigma-Aldrich) according to the manufacturer's recommended protocols, followed by LC/MS analysis of the tryptic peptides using the conditions as previously described (16).

Preparation of mutant *E. coli* LpxC

Mutant *E. coli* LpxC proteins were prepared with the QuikChange® PCR mutagenesis kit (Stratagene) using the pET-11:*E. coli lpxC* plasmid and purified as previously described (18). The six cysteines were mutated as follows: C63S, C65A, C125A, C207A, C214N, C250A. The activities of the mutant proteins and wild type *E. coli* LpxC were assayed in cell-free extracts as previously described (14), except that the cultures were grown at 37 °C and induced

with 1 mM isopropyl β -D-thiogalactopyranoside when the A_{600} reached 0.5, followed by overnight incubation at 18 °C with shaking.

E. coli LpxC C207A was purified as previously described (14), and the kinetic characterization reported herein utilized this purified protein.

Synthesis of 1-68A analogs

All chemical reagents were obtained from commercial suppliers and were used without further purification. Analytical thin-layer chromatography was conducted on Analtech Uniplat silica gel plates with detection by UV light. Reverse phase HPLC was performed on a Varian Prostar system using Microsorb C18 reverse-phase columns (analytical: 4.6 mm ID $\times$ 25 cm, 1 mL/min), and UV detection was carried out at 254 nm on a Varian ProStar 325 detector.

3,4-Dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Aa)—3,4-

Dihydroxybenzaldehyde (9.9 mg, 0.072 μ mol) was added to a solution of aminooxyuridine (25.0 mg, 0.0964 μ mol) in 1% acetic acid/DMF (0.6 mL). The resulting solution was stirred in the dark for 4 d at room temperature under nitrogen, the solvent was removed *in vacuo*, and the crude product mixture was purified by reversed-phase HPLC to yield a white solid (13.5 mg, 50%). R_f : 0.75 (7:2:1 ethyl acetate:methanol:water, UV). ^1H NMR (400 MHz, *d*-methanol) δ 8.02 (1H, s), 7.80 (1H, d, J = 8.0 Hz), 7.10 (1H, d, J = 2.0 Hz), 6.91–6.88 (1H, m), 6.76 (1H, d, J = 8.0 Hz), 5.89 (1H, d, J = 4.8 Hz), 5.60 (1H, d, J = 8.0 Hz), 4.42 (1H, dd, J = 12.4, 2.8 Hz), 4.32 (1H, dd, J = 12.4, 3.6 Hz), 4.23–4.18 (2H, m), 4.13–4.11 (1H, m); ^{13}C NMR (100 MHz, *d*-methanol) δ 164.67, 150.90, 149.49, 147.64, 145.36, 140.77, 123.54, 120.22, 114.81, 112.42, 101.32, 89.11, 83.26, 74.01, 72.84, 69.92; HRMS (FAB): Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{O}_8$ [$\text{M}+\text{H}$] $^+$ 380.1094, found 380.1090.

2,4-Dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Ab)—2,4-

Dihydroxybenzaldehyde (9.9 mg, 0.072 μ mol) was dissolved in a solution aminooxyuridine (25.0 mg, 0.0964 μ mol) in 1% acetic acid in DMF (0.6 mL). The resulting solution was stirred for 3 d in the dark at room temperature under nitrogen, the solvent was removed *in vacuo*, and the crude product mixture was purified by reversed-phase HPLC to yield a white solid (11.6 mg, 43%). R_f : 0.74 (7:2:1 ethyl acetate:methanol:water, UV). ^1H NMR (400 MHz, *d*-methanol) δ 8.28 (1H, s), 7.75 (1H, d, J = 8.0 Hz), 7.18 (1H, d, J = 8.4 Hz), 6.35 (1H, dd, J = 8.4, 2.4 Hz), 6.31 (1H, d, J = 2.4 Hz), 5.88 (1H, d, J = 4.4 Hz), 5.64 (1H, d, J = 8.4 Hz), 4.45 (1H, m), 4.35 (1H, m), 4.23–4.16 (3H, m); ^{13}C NMR (100 MHz, *d*-methanol) δ 164.68, 160.69, 158.65, 150.83, 150.68, 140.86, 130.96, 108.71, 107.43, 102.22, 101.31, 89.73, 82.82, 73.81, 73.14, 69.76; HRMS (FAB): Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{O}_8$ [$\text{M}+\text{H}$] $^+$ 380.1094, found 380.1085.

2,3-Dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Ac)—2,3-

Dihydroxybenzaldehyde (9.9 mg, 0.072 μ mol) was added to a solution of aminooxyuridine (25.0 mg, 0.0964 μ mol) in 1% acetic acid/DMF (0.6 mL). The resulting solution was stirred for 4 d in the dark at room temperature, the solvent was removed *in vacuo*, and the crude product mixture was purified by reversed-phase HPLC to yield a white solid (23.1 mg, 85%). R_f : 0.75 (7:2:1 ethyl acetate:methanol:water, UV). ^1H NMR (400 MHz, *d*-methanol) δ 8.41 (1H, s), 7.74 (1H, d, J = 8.0 Hz), 6.92 (1H, m), 6.87 (1H, m), 6.76 (1H, m), 5.90 (1H, d, J = 4.4 Hz), 5.65 (1H, d, J = 8.4 Hz), 4.53 (1H, m), 4.43 (1H, m), 4.22 (3H, m); ^{13}C NMR (100 MHz, *d*-methanol) δ 164.65, 150.82, 150.46, 150.45, 145.21, 144.94, 140.83, 119.97, 119.40, 116.86, 101.35, 89.84, 82.74, 73.77, 73.40, 69.72; HRMS (FAB): Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{O}_8$ [$\text{M}+\text{H}$] $^+$ 380.1094, found 380.1086.

3,4,5-Trihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Ad)—3,4,5-

Trihydroxybenzaldehyde (11.1 mg, 0.0720 μmol) was dissolved in a solution of aminooxyuridine (25.0 mg, 0.0964 μmol) in 1% acetic acid/DMF (0.6 mL). The resulting solution was stirred for 4 d at room temperature, the solvent was removed *in vacuo*, and the crude product mixture was purified by reversed-phase HPLC to yield a white solid (6.1 mg, 22%). R_f : 0.70 (7:2:1 ethyl acetate:methanol:water, UV). ^1H NMR (300 MHz, *d*-methanol) δ 7.95 (1H, s), 7.81 (1H, d, J = 8.1 Hz), 6.64 (2H, s), 5.91 (1H, d, J = 4.8 Hz), 5.62 (1H, d, J = 8.1 Hz), 4.43 (1H, dd, J = 12.6, 2.7 Hz), 4.33 (1H, dd, J = 12.6, 3.3 Hz), 4.25-4.18 (2H, m), 4.13 (1H, app t, J = 4.8 Hz); ^{13}C NMR; (100 MHz, *d*-methanol) δ 161.52, 160.64, 160.65, 150.67, 150.66, 140.84, 130.91, 108.68, 107.40, 102.19, 101.28, 89.77, 82.58, 73.83, 73.11, 69.82; HRMS (ESI): Calcd for $\text{C}_{16}\text{H}_{16}\text{N}_3\text{O}_9$ $[\text{M}-\text{H}]^-$ 394.0892, found 394.0881.

3,4-dimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Ae)—3,4-Dimethoxy

benzaldehyde (4.90 mg, 0.0296 μmol) was dissolved in a solution of aminooxyuridine (10.0 mg, 0.0385 μmol) in 1% acetic acid/DMF. The resulting solution was stirred in the dark for 1 d at room temperature under an atmosphere of nitrogen. The crude mixture was then concentrated *in vacuo*, and purified by reversed-phase HPLC to yield a white solid (3.4 mg, 28%). ^1H NMR (400 MHz, *d*-methanol) δ 8.16 (1H, s), 7.82 (1H, d, J = 8.4 Hz), 7.32 (1H, s), 7.15 (1H, d, J = 8), 7.0 (1H, d, J = 8.4), 5.92 (1H, d, J = 4.8), 5.64 (1H, d, J = 8.4), 4.5 (1H, dd, J = 12.4, 3.3), 4.41 (1H, dd, J = 12.4, 3.2), 4.24 (2H, m), 4.18 (1H, app t, J = 4.4), 3.88 (3H, s), 3.87 (3H, s); ^{13}C NMR (100 MHz, *d*-methanol) δ 153.38, 150.10, 148.17, 148.11, 141.17, 139.93, 139.86, 121.22, 110.30, 107.13, 100.03, 89.01, 81.78, 71.98, 71.30, 69.23, 55.79, 55.81; HRMS (ESI): Calcd for $\text{C}_{16}\text{H}_{16}\text{N}_3\text{O}_9$ $[\text{M}+\text{H}]^+$ 408.3746, found 408.3822.

2,3,4-Trimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime (1-68Af)—2,3,4-

Trimethoxybenzaldehyde (5.80 mg, 0.0296 μmol) was added to a solution of aminooxyuridine (10.0 mg, 0.0385 μmol) in 1% acetic acid/DMF (1 mL). The resulting solution was stirred in the dark for 1 d at room temperature under an atmosphere of nitrogen. The crude product was then concentrated *in vacuo* and purified by reversed-phase HPLC to yield a white solid (7.3 mg, 56%). ^1H NMR (400 MHz, *d*-methanol) δ 8.35 (1H, s), 7.84 (1H, d, J = 8.0 Hz), 7.52 (1H, d, J = 8.8), 6.85 (1H, d, J = 9.2), 5.92 (1H, d, J = 4.4), 5.63 (1H, d, J = 8.0 Hz), 4.51 (1H, m), 4.48 (1H, m), 4.41 (1H, d, J = 3.2 Hz), 4.38 (1H, m), 4.25-4.24 (2H, m), 4.18-4.16 (1H, t, J = 4.4), 3.91 (3H, s) 3.90 (3H, s) 3.85 (3H, s); ^{13}C NMR (100 MHz, *d*-methanol) δ 164.65, 155.62, 152.46, 150.86, 144.89, 141.93, 140.79, 120.91, 117.88, 107.94, 101.19, 89.39, 83.07, 74.02, 72.95, 69.86, 60.84, 59.80, 55.12; HRMS (ESI): Calcd for $\text{C}_{16}\text{H}_{16}\text{N}_3\text{O}_9$ $[\text{M}+\text{H}]^+$ 438.4001, found 438.4102.

Results

Identification of a uridine-based LpxC inhibitor

An initial screen of a uridine-based library (20) revealed six compounds that inhibited *E. coli* LpxC activity by more than 40%. Two related compounds, 1-68A and 2-68A, contain a 2,3,4 tri-hydroxy benzyl moiety appended to uridine through an aminooxy or glycyaminooxy linkage, respectively (Figure 2). These compounds were previously identified as competitive inhibitors of the mucin *N*-acetyl- α -galactosaminyltransferase family (ppGalNAcT's) (20). Compounds 1-68A and 2-68A exhibited IC_{50} values against *E. coli* LpxC of 27 ± 5 μM and 120 ± 30 μM , respectively, using single time-point assays. As depicted in Figure 2C, the best fit of Eq. 1 specified a Hill slope of 0.7 for each curve, indicating a shallower dose-response curve than expected for a rapidly reversible inhibitor.

Kinetics of 1-68A inhibition

The reaction velocity of *E. coli* LpxC in the presence of 1-68A decreased as the reaction progressed, as shown in Figure 3A, indicating time-dependent inhibition. Enzyme inhibition appeared kinetically irreversible because rapid dilution (Figure 3B) or dialysis (Figure 3C) of the LpxC – 1-68A complex failed to restore enzyme activity. Product accumulation data was fitted to a kinetically irreversible, time-dependent inhibition model (Eq. 2, Figure 3A) to derive a k_{obs} value for each concentration of inhibitor; k_{obs} is the pseudo first-order rate constant of enzyme inactivation. The plateau of k_{obs} at high 1-68A concentrations, as seen in Figure 3D, indicates the rate of formation of the terminal complex is saturable at high inhibitor concentrations. The kinetics of 1-68A binding to *E. coli* LpxC are most consistent with the two-step, kinetically irreversible mechanism shown in Scheme 1 (22). Using non-linear curve fitting, values for the kinetic parameters k_{inact} (the maximal rate of enzyme inactivation) and K_I (the inhibitor concentration at which k_{obs} is one-half of k_{inact}) were determined to be $1.7 \pm 0.3 \text{ min}^{-1}$ and $54 \pm 7 \text{ }\mu\text{M}$, respectively, using Eqs. 3 and 4.

To determine the binding mode of 1-68A, the effect of substrate concentration on k_{obs} at two 1-68A concentrations (10 and 25 μM) was investigated. The diminishing magnitude of k_{obs} as substrate increases, as seen in Figure 3E, is typical of a competitive inhibitor (22).

The uridine-binding site of LpxC (10), which binds the uridine moiety of UDP-3-*O*-acetyl-GlcNAc with low millimolar affinity (13), likely also binds the uridine moiety of 1-68A. If UDP and 1-68A compete for a binding site, millimolar concentrations of UDP would slow the formation of a kinetically-irreversible 1-68A – LpxC complex. Indeed, 100 mM UDP was sufficient to reduce the rate of *E. coli* LpxC inactivation by 1-68A (in the absence of substrate) more than 5-fold, as shown in Figure 3F.

Wild-type *E. coli* LpxC displays time-dependent inhibition with CHIR-090 (18). A mutant of *E. coli* LpxC (Q202W / G210S) loses the time-dependence of CHIR-090 inhibition (18). However, this mutant is still sensitive to inhibition by 1-68A in a time-dependent manner (data not shown). This suggests that despite kinetic similarities, the mechanism of 1-68A inhibition is significantly different than CHIR-090 inhibition.

Role of a thiol in 1-68A inhibition

Given the instability of 1-68A in air and its protection by reducing agents, the effects of reducing agents were explored on the 1-68A inhibition of LpxC. The reducing agents glutathione and dithiothreitol diminished the inhibition of LpxC by 1-68A (Figure 4A). Dithiothreitol is likewise capable of reversing 1-68A inhibition, as seen in Figure 4B, but does not effect the inhibition of the more potent *E. coli* LpxC inhibitors CHIR-090, BB-78485 and L-161,240 (data not shown).

The reactivity of free thiols depends strongly on the pH. Therefore, the pH dependency of k_{obs} at a fixed 1-68A concentration (1 μM) was determined as previously described (8,23). A plot of these data, shown in Figure 4C, reveals that k_{obs} has a pK_a of at least 9.2. The pH-rate profile of LpxC was monitored as a control with 5 μM substrate (24). Both the effect of reductants on complex formation and the pH dependency of k_{obs} are suggestive that a thiolate moiety is involved in 1-68A inhibition.

E. coli LpxC variants with mutated cysteine residues were constructed to test the role of a thiol in 1-68A inhibition. *E. coli* LpxC contains six, non-conserved cysteine residues. One mutant enzyme, C207A, was much less sensitive to 1-68A inhibition (compare the first 8 min of Figure 4B and D) suggesting Cys-207 is necessary to form the E-I complex. Mutant enzymes containing mutations of the other five cysteines were as sensitive to 1-68A as the wild-type enzyme, and all mutant proteins were nearly as active as the wild type (data not shown). The

residual sensitivity of *E. coli* LpxC C207A may reflect the binding of 1-68A in the active site without the formation of a kinetically irreversible complex, or it may be due to interaction with the remaining five cysteine residues. However, inhibition of LpxC C207A by 1-68A was unaffected by dithiothreitol (Figure 4D) and the inhibition is reversible, strongly suggesting Cys-207 is specifically involved in time-dependent inhibition. Furthermore, the fractional activity (v_i / v_o) of the mutant enzyme in the presence of 0.5 mM 1-68A was the same at pH 7.4 and 9.0 (data not shown).

1-68A covalently modifies *E. coli* LpxC

To determine whether the observed kinetic irreversibility of 1-68A inhibition was due to tight binding or covalent modification of LpxC, protein mass spectrometry of the 1-68A – *E. coli* LpxC complex was performed. The mass of the 1-68A – *E. coli* LpxC complex was 394 Da greater than that of the uninhibited enzyme as determined by electrospray-ionization mass spectrometry (ESI-MS) (Figure 5A-C). This shift is consistent with the incorporation of one molecule of 1-68A (monoisotopic mass = 395.10 Da) minus one hydrogen atom. The mass spectrum (Figure 5C) demonstrated that a small percentage of *E. coli* LpxC increased by 788 Da, consistent with the incorporation of two molecules of 1-68A minus two hydrogens. Efforts to locate the site of LpxC modification through proteolytic digestion and MS analysis of the enzyme:inhibitor complex were unsuccessful. No 1-68A-modified tryptic peptides were detected. It is possible that standard proteolytic digestions with trypsin (overnight incubation at 37 °C) result in degradation of the complex.

To demonstrate that a covalent complex can form between a thiol-containing agent and 1-68A, a model thiol-containing compound *N*-acetylcysteine-methylester was incubated with 1-68A. MS studies revealed the formation of a covalent complex between *N*-acetylcysteine-methylester and 1-68A (Figure 5D). The mass of this complex and its MS/MS analysis are consistent with the structure shown in Figures 5D and 5E. Together, the mass spectral analyses of the *E. coli* LpxC – 1-68A and *N*-acetylcysteine-methylester – 1-68A complexes are consistent with a mechanism whereby 1-68A inhibits *E. coli* LpxC by covalent modification of a cysteine residue.

Sensitivity of LpxC to 1-68A analogs

The inhibitory effects of 1-68A analogs with variations of the 2,3,4-trihydroxy benzyl moiety were tested (Figure 6). Only 1-68Aa, lacking a hydroxyl at the 2 position, inhibited *E. coli* LpxC as potently as 1-68A. Two compounds that retain the 3 position hydroxyl, 1-68Ac and 1-68Ad, were weak inhibitors. An isomer of 1-68A, 1-68Ad, contains a 5 position hydroxyl and exhibits greatly reduced inhibitory potency. 1-68Ab, a compound that does not contain the 3 position hydroxyl, was ineffective at all concentrations tested. The methyl ester-containing compounds 1-68Ae and 1-68Af were ineffective as well. Based on these data it appears the 3 and 4 position hydroxyls are critical for potent inhibition and removing or blocking them with methyl groups diminished inhibition at the concentrations tested. It was not determined whether these analogs are irreversible inhibitors.

By testing the inhibition of a broad range of purified LpxC orthologs by 1-68A and its analogs, it was determined that 1-68Aa is a more effective inhibitor of *Helicobacter pylori* LpxC and *Rhizobium leguminosarum* LpxC than the parent compound 1-68A (Table 1). Both *E. coli* LpxC and *H. pylori* LpxC are inhibited by 1-68Aa in a time-dependent manner; furthermore, inhibition does not occur in the presence of 2 mM dithiothreitol and 50 μ M 1-68Aa (data not shown). Though both *R. leguminosarum* and *H. pylori* LpxC contain cysteines, none of these are near Cys-207 of *E. coli* LpxC based on the primary sequence alignments (Figure S1). Without full structural information, it is not clear whether *R. leguminosarum* and *H. pylori* LpxC have cysteine residues proximal to their uridine-binding pockets.

Discussion

Inhibitors targeting the UDP pocket

In this study 1-68A was identified as a two-step, covalent inhibitor of *E. coli* LpxC. 1-68A may be viewed as a competitive inhibitor of *E. coli* LpxC in that it binds to the UDP-binding site (Figure 3F) and thus represents a new class of LpxC inhibitors. Although 1-68A lacks antibiotic activity (data not shown), it nevertheless demonstrates that the UDP pocket can be targeted for inhibitor discovery. Given that none of the potent LpxC inhibitors with antibiotic activity target the UDP pocket, addition of a UDP analog might enhance binding and specificity. In theory, an inhibitor developed through a multivalency approach may bind to LpxC with a dissociation constant that is the product of the two individual components (25). Addition of a moiety with 1 mM affinity to a tight-binding inhibitor, like CHIR-090, could therefore enhance binding 1000-fold.

Mechanism of inhibition

It is likely that the non-covalent interaction of 1-68A with the UDP-binding site on LpxC is the fast step that forms the EI complex (Scheme 1), followed by a slow step to form the E-I complex. Consistent with this kinetic scheme, *E. coli* LpxC C207A is much less sensitive to 1-68A when compared to wild-type *E. coli* LpxC (Figure 4), and does not form an E-I complex. This suggests that the EI complex found with *E. coli* LpxC C207A is comparable to the initial EI complex found with wild-type *E. coli* LpxC.

The second step of inhibition, the formation of a covalent E-I complex, requires high pH and Cys-207. Consistent with this notion, the ESI-MS analysis indicated that 1-68A reacts with a cysteine-containing model peptide (*N*-acetylcysteine-methylester) or with multiple sites on *E. coli* LpxC to form a covalent complex. However, the predominant form of *E. coli* LpxC has reacted with only one equivalent of 1-68A (Figure 5). Given that *E. coli* LpxC C207A is much less sensitive to 1-68A inhibition when compared to wild-type *E. coli* LpxC (Figure 4), and it does not form an E-I complex, Cys-207 is likely the primary site of 1-68A modification. However, it is not possible to exclude the possibility that, unlike the studies with *N*-acetylcysteine-methylester, 1-68A does not react with a cysteine residue of LpxC. In this scenario, Cys-207 would be required to form the complex though is itself not permanently modified.

The finding that UDP can delay 1-68A inhibition of LpxC is evidence that 1-68A engages the UDP binding pocket. Comparison of an *E. coli* LpxC homology model and a crystal structure of the *A. aeolicus* LpxC – UDP complex (10) indicates that Cys-207 is located <10 Å from C-5 of the ribose ring (Figure 7), a distance that is approximately equal to the length of the aminoxy and tri-hydroxy benzene moieties of 1-68A (Figure 2). Although the role of Cys-207 is not well defined, the model of the *E. coli* LpxC structure indicates that all of the other cysteine residues are farther from the UDP-binding site and therefore less likely to mediate LpxC inhibition by 1-68A.

In an effort to establish the importance of various substituents for potency, analogs of 1-68A in which the hydroxyls at either positions 3 or 4 are absent (1-68Ab and 1-68Ac) or blocked (1-68Ae and 1-68Af) were assayed and found to be poor inhibitors (Figure 5). However, the absence of the 2 position hydroxyl (1-68Aa) had little effect on inhibition (Figure 5). It is possible the 3 and 4 position hydroxyls are necessary to facilitate the formation of a reactive species. Addition of a hydroxyl at the 5 position (1-68Ad) may prevent the formation of a reactive species. These results suggest the tri-hydroxy benzene moiety, rather than the nucleoside or aminoxy linkage, is responsible for the formation of the covalent E-I complex.

A similar covalent inactivator of pyruvic-, α -ketoglutaric-, and succinic-dehydrogenases by γ -L-glutaminy 3,4-benzoquinone has been described (26).

1-68A inhibits LpxC and ppGalNAcT2 via different mechanisms

Previously 1-68A was identified as an inhibitor of mucin ppGalNAcT2 (20), a glycosyl transferase with no obvious homology to LpxC. However, 1-68A appears to be a fully reversible inhibitor of ppGalNAcT2, and inhibition occurs in the presence of 40 mM β -mercaptoethanol (20). In addition, none of the 1-68A analogs reported here (Figure 6) were inhibitors of ppGalNAcT2 (Leavy and Bertozzi, unpublished results). These data suggest 1-68A inhibits LpxC and ppGalNAcT2 through different mechanisms.

Conclusion

1-68A represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Dr. Johannes Rudolph and Dr. K. V. Rajagopalan for helpful discussions and Dr. Craig Bartling for aliquoting the uridine-based inhibitor library.

This research was supported by NIH grants GM-51310 to C. R. H. Raetz and AI-055588 to P. Zhou. A. Barb was supported by the Cellular and Molecular Biology training grant GM-07184 to Duke University. T. Leavy was supported by NIH grant 5R01GM066047.

List of Abbreviations

UDP-3-<i>O</i>-acetyl-GlcNAc	UDP-3- <i>O</i> -(<i>R</i> -3-hydroxyacetyl)- <i>N</i> -acetylglucosamine
DMSO	dimethyl sulfoxide
ESI-MS	electrospray ionization mass spectrometry
Kdo	3-deoxy- β - <i>manno</i> -octulosonic acid
IC₅₀	concentration of half maximal inhibition
LC	liquid chromatography
LpxC	UDP-3- <i>O</i> -(<i>R</i> -3-hydroxyacetyl)- <i>N</i> -acetylglucosamine deacetylase
ppGalNAcT2	<i>N</i> -acetyl- α -galactosaminyltransferase
UDP	

uridine diphosphate

References

- Walsh C. Molecular mechanisms that confer antibacterial drug resistance. *Nature* 2000;406:775–781. [PubMed: 10963607]
- Projan SJ, Youngman PJ. Antimicrobials: new solutions badly needed. *Curr Opin Microbiol* 2002;5:463–465. [PubMed: 12354551]
- Russell, AD.; Chopra, I. Understanding antibacterial action and resistance. E. Horwood; New York: 1990.
- Wyckoff TJ, Raetz CRH, Jackman JE. Antibacterial and anti-inflammatory agents that target endotoxin. *Trends Microbiol* 1998;6:154–159. [PubMed: 9587193]
- Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. *Annu Rev Biochem* 2002;71:635–700. [PubMed: 12045108]
- Raetz, CRH. *Escherichia coli* and *Salmonella*: cellular and molecular biology. Vol. 2nd. ASM Press; Washington, D.C.: 1996. p. 1035-1063.
- Coggins BE, Li X, McClerren AL, Hindsgaul O, Raetz CRH, Zhou P. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. *Nat Struct Biol* 2003;10:645–651. [PubMed: 12833153]
- Coggins BE, McClerren AL, Jiang L, Li X, Rudolph J, Hindsgaul O, Raetz CRH, Zhou P. Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design. *Biochemistry* 2005;44:1114–1126. [PubMed: 15667205]
- Gennadios HA, Whittington DA, Li X, Fierke CA, Christianson DW. Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase. *Biochemistry* 2006;45:7940–7948. [PubMed: 16800620]
- Gennadios HA, Christianson DW. Binding of Uridine 5'-Diphosphate in the "Basic Patch" of the Zinc Deacetylase LpxC and Implications for Substrate Binding. *Biochemistry* 2006;45:15216–15223. [PubMed: 17176043]
- Williamson JM, Anderson MS, Raetz CRH. Acyl-acyl carrier protein specificity of UDP-GlcNAc acyltransferases from gram-negative bacteria: relationship to lipid A structure. *J Bacteriol* 1991;173:3591–3596. [PubMed: 1904441]
- Hyland SA, Eveland SS, Anderson MS. Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from *Pseudomonas aeruginosa*: a metalloamidase of the lipid A biosynthesis pathway. *J Bacteriol* 1997;179:2029–2037. [PubMed: 9068651]
- Hernick M, Fierke CA. Catalytic Mechanism and Molecular Recognition of *E. coli* UDP-3-O-(R-3-Hydroxymyristoyl)-N-acetylglucosamine Deacetylase Probed by Mutagenesis. *Biochemistry* 2006;45:15240–15248. [PubMed: 17176046]
- Barb AW, McClerren AL, Karnam S, Reynolds CM, Zhou P, Raetz CRH. Inhibition of Lipid A Biosynthesis as the Primary Mechanism of CHIR-090 Antibiotic Activity in *Escherichia coli*. *Biochemistry* 2007;46:3793–3802. [PubMed: 17335290]
- Clements JM, Coignard F, Johnson I, Chandler S, Palan S, Waller A, Wijkman J, Hunter MG. Antibacterial activities and characterization of novel inhibitors of LpxC. *Antimicrob Agents Chemother* 2002;46:1793–1799. [PubMed: 12019092]
- McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, Rudolph J, Raetz CRH. A Slow, Tight-Binding Inhibitor of the Zinc-Dependent Deacetylase LpxC of Lipid A Biosynthesis with Antibiotic Activity Comparable to Ciprofloxacin. *Biochemistry* 2005;44:16574–16583. [PubMed: 16342948]
- Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, Chen MH, Patchett AA, Galloway SM, Hyland SA, Anderson MS, Raetz CRH. Antibacterial agents that inhibit lipid A biosynthesis. *Science* 1996;274:980–982. [PubMed: 8875939]
- Barb AW, Jiang L, Raetz CRH, Zhou P. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding. *Proc Natl Acad Sci U S A* 2007;104:18433–18438. [PubMed: 18025458]
- Mochalkin I, Knafels JD, Lightle S. Crystal structure of LpxC from *Pseudomonas aeruginosa* complexed with the potent BB-78485 inhibitor. *Protein Sci* 2008;17:450–457. [PubMed: 18287278]

20. Hang HC, Yu C, Ten Hagen KG, Tian E, Winans KA, Tabak LA, Bertozzi CR. Small molecule inhibitors of mucin-type O-linked glycosylation from a uridine-based library. *Chem Biol* 2004;11:337–345. [PubMed: 15123263]
21. Jackman JE, Raetz CRH, Fierke CA. UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine Deacetylase of *Escherichia coli* Is a Zinc Metalloenzyme. *Biochemistry* 1999;38:1902–1911. [PubMed: 10026271]
22. Copeland, RA. Evaluation of enzyme inhibitors in drug discovery : a guide for medicinal chemists and pharmacologists. Wiley-Interscience; Hoboken, N.J.: 2005.
23. McClerren AL, Zhou P, Guan Z, Raetz CRH, Rudolph J. Kinetic analysis of the zinc-dependent deacetylase in the lipid A biosynthetic pathway. *Biochemistry* 2005;44:1106–1113. [PubMed: 15667204]
24. Hernick M, Gennadios HA, Whittington DA, Rusche KM, Christianson DW, Fierke CA. UDP-3-*O*-((*R*)-3-hydroxymyristoyl)-*N*-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism. *J Biol Chem* 2005;280:16969–16978. [PubMed: 15705580]
25. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. *Science* 1996;274:1531–1534. [PubMed: 8929414]
26. Weaver RF, Rajagopalan KV, Handler P, Jeffs P, Byrne WL, Rosenthal D. Isolation of γ -l-glutaminy 4-hydroxybenzene and γ -l-glutaminy 3,4-benzoquinone: a natural sulfhydryl reagent, from sporulating gill tissue of the mushroom *Agaricus bisporus*. *Proc Natl Acad Sci U S A* 1970;67:1050–1056. [PubMed: 5289001]

Figure 1.

Reaction catalyzed by LpxC and the structure of *E. coli* lipid A. The biosynthesis of lipid A begins with the 3-*O*-acylation of UDP-*N*-acetylglucosamine by the cytosolic enzyme LpxA (5). In the first irreversible (committed) reaction of the pathway, the deacetylase LpxC unblocks the nitrogen at the 2 position of the glucosamine ring for subsequent acylation by LpxD (5). Seven downstream reactions produce Kdo₂-lipid A, the hydrophobic membrane anchor of lipopolysaccharide (5).

Figure 2.

Uridine-based inhibitors of *E. coli* LpxC. Two compounds, 1-68A (**Panel A**) and 2-68A (**Panel B**), were identified that inhibited *E. coli* LpxC with apparent mid- μM IC_{50} s. (**Panel C**) Analysis of concentration-response plots fitted with Eq. 1 gave IC_{50} values of 27 μM and 120 μM for 1-68A (black circles) and 2-68A (open squares), respectively, where $H=0.7$.

Figure 3.

Slow, kinetically irreversible and competitive inhibition of *E. coli* LpxC by 1-68A. (**Panel A**) Progress curves for product formation when reactions are initiated by the addition of enzyme in the presence 0 μM (black circles), 0.5 μM (black Xs), 2 μM (open circles), 5 μM (black diamonds), 10 μM (open squares), 17.5 μM (open triangles), or 50 μM (black pluses) 1-68A as fitted with Eq. 2. Data is representative of two separate experiments. (**Panel B**) Rapid dilution of the *E. coli* LpxC – 1-68A complex. (**Panel C**) *E. coli* LpxC activity following dialysis of the LpxC – 1-68A complex. (**Panel D**) A plot of the observed pseudo first-order rate constant for the formation of the E-I complex (k_{obs}) as fitted with Eq. 3. Repeat experiments (not shown) gave identical results (within 10 %). (**Panel E**) A plot showing the effect of

increasing substrate concentrations on the observed first order rate constant (k_{obs}) in the presence of 10 μM (open circles) or 25 μM (*black* squares) 1-68A. Eq. 4 was fitted to these data. These plots include data from three independent experiments. **(Panel F)** The fractional activity of LpxC after a preincubation in the presence of 50 μM 1-68A (*black* diamonds) with or (*black* Xs) without 100 mM UDP. The fit of a first-order, decaying exponential ($v_i / v_o = e^{-kt}$) for each data set is shown as a line.

Figure 4.

Inhibition of *E. coli* LpxC by 1-68A depends upon a thiol group. **(Panel A)** Effect of glutathione or dithiothreitol (DTT) on 1-68A inhibition of *E. coli* LpxC activity. **(Panel B)** Reactions containing 0 μM (black squares) or 50 μM (open circles) 1-68A were initiated with 0.1 nM *E. coli* LpxC. Both reactions progressed for 9 min, at which point dithiothreitol was added (as indicated by the arrow) to a final concentration of 2 mM. The reduced velocity of the 0 μM reaction after 9 min is not due to dilution but rather dithiothreitol is a weak competitive inhibitor *E. coli* LpxC (data not shown). **(Panel C)** pH rate profile of wild-type *E. coli* LpxC specific activity (open circles) and the rate (k_{obs}) of 1-68A inhibition (black squares). The bell-shaped profile is fit with a pK_1 of 5.9 and a pK_2 of 8.0. The k_{obs} profile is fitted with a curve describing a pK_a of at least 9.2. **(Panel D)** Reactions containing 0 μM (black squares) or 2 mM (open circles) 1-68A were initiated with 0.1 nM *E. coli* LpxC C207A. Both reactions progressed for 9 min, at which point dithiothreitol was added (as indicated by the arrow) to a final concentration of 2 mM. Data is representative of two separate experiments.

Figure 5.

ESI-MS analysis of the *E. coli* LpxC – 1-68A complex. (**Panel A**) The LC-elution profile of *E. coli* LpxC preincubated with equimolar 1-68A, shown as the extracted ion current. Positive ion (**Panel B**) and deconvoluted (**Panel C**) mass spectra of *E. coli* LpxC from the 16-22 min region of the LC elution shown in Panel A. The observed mass of the *E. coli* LpxC polypeptide was 33,952 Da (data not shown). (**Panel D**) Mass spectrum of products formed after incubating *N*-acetylcysteine-methylester and 1-68A at pH 7.4. Note: The proposed structure of **b**, i.e. covalent complex of *N*-acetylcysteine-methylester and 1-68A, was proposed based on exact mass measurement and MS/MS, which would not delineate position isomers. (**Panel E**) MS/MS analysis of the “b” ion in **Panel D**.

Figure 6. *E. coli*
LpxC inhibition by 1-68A analogs. Analogs of 1-68A containing variable substituents on the benzene ring were synthesized and tested for inhibition of *E. coli* LpxC. Of this series, only 1-68Aa was of comparable potency to 1-68A, and is likewise a time-dependent inhibitor of *E. coli* and *Helicobacter pylori* LpxC (data not shown).

Figure 7. Potential binding mode of UDP and location of cysteine residues in the *E. coli* LpxC active site. This model is based upon an *A. aeolicus* LpxC – UDP complex, as determined by x-ray crystallography (2IER). The zinc ion is shown as an *orange* sphere. This figure was prepared using PyMOL.

Table 1Inhibition of LpxC orthologs* by 50 μ M 1-68A or 1-68Aa

LpxC Source	Percent Inhibition	
	1-68A	1-68Aa
<i>Escherichia coli</i>	80% $\pm$ 6%	60% $\pm$ 14%
<i>Pseudomonas aeruginosa</i>	n.i.	n.i.
<i>Neisseria meningitidis</i>	6% $\pm$ 1%	9% $\pm$ 5%
<i>Helicobacter pylori</i>	21% $\pm$ 1%	41% $\pm$ 1%
<i>Rhizobium leguminosarum</i>	n.i.	49% $\pm$ 10%
<i>Aquifex aeolicus</i>	n.i.	13% $\pm$ 5%

n.i. – not inhibited

* no inhibition at 50 μ M was observed with the remaining 1-68A analogs